• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/19/25 8:41:28 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    mo-20250513
    false000076418000007641802025-05-132025-05-130000764180mo:CommonStock0.3313ParValueMember2025-05-132025-05-130000764180mo:CommonStock1.700NotesDue2025Member2025-05-132025-05-130000764180mo:CommonStock2.200NotesDue2027Member2025-05-132025-05-130000764180mo:CommonStock3.125NotesDue2031Member2025-05-132025-05-13

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     ____________________________________________________________________________________________________________
    FORM 8-K
    ________________________________________________________________________________________________________________
     CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 13, 2025
    ________________________________________________________________________________________________________________
    ALTRIA GROUP, INC.
    (Exact name of registrant as specified in its charter)
    ______________________________________________________________________________________________________________
    Virginia  1-08940  13-3260245
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)  (I.R.S. Employer
    Identification No.)
    6601 West Broad Street,Richmond,Virginia23230
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (804) 274-2200
    _______________________________________________________________________________________________________________
    (Former name or former address, if changed since last report.)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
                   Title of each class               
    Trading SymbolsName of each exchange on which registered
    Common Stock, $0.33 1/3 par value
    MONew York Stock Exchange
    1.700% Notes due 2025
    MO25New York Stock Exchange
    2.200% Notes due 2027
    MO27New York Stock Exchange
    3.125% Notes due 2031
    MO31New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    Controller Transition
    On May 13, 2025, Steven D’Ambrosia, Vice President and Controller of Altria Group, Inc. (“Altria”), announced his intention to retire as Vice President and Controller effective July 31, 2025.
    On May 15, 2025, Altria’s Board of Directors (the “Board”) elected Katie F. Patterson to become Vice President and Controller of Altria, effective upon Mr. D’Ambrosia’s retirement.
    Ms. Patterson, age 39, currently serves as Senior Director, External Reporting, Corporate and Benefits, Altria Client Services LLC, a wholly owned subsidiary of Altria, a position she has held since June 2024. Prior to this role, she served as Senior Director, Accounting and Reporting from February 2019 until June 2024. Since 2013, she has been continuously employed by Altria subsidiaries in various accounting, financial reporting, investor relations, treasury, and financial planning and analysis positions.
    As a result of her election, Ms. Patterson will become a salary band F employee effective August 1, 2025. The Compensation and Talent Development Committee of the Board set her annual base salary at $300,000, which is consistent with salaries for band F employees and market positioning for the role.
    Ms. Patterson’s annual incentive award plan, long-term incentive plan (“LTIP”) and annual equity award targets are consistent with current salary band F targets as follows: Ms. Patterson’s annual incentive award plan target will be 50% of base salary, her LTIP award target will be $112,900 over a three-year performance cycle with three cycles running concurrently and her annual equity award target will be $165,000. Ms. Patterson will be eligible to participate in the same compensation programs as Altria’s other executive officers.
    Altria’s annual incentive award plan, long-term incentives and other elements of its executive compensation program are more fully described under the “Compensation Discussion and Analysis” section of Altria’s proxy statement for its 2025 Annual Meeting of Shareholders filed with the Securities and Exchange Commission on April 3, 2025 (the “2025 Proxy Statement”).
    Equity Compensation Plans
    On May 15, 2025, Altria held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, shareholders approved Altria’s (1) 2025 Performance Incentive Plan (the “2025 PIP”) and (2) 2025 Stock Compensation Plan for Non-Employee Directors (the “2025 Non-Employee Director Plan”), each of which had been previously approved by the Board subject to shareholder approval.
    The 2025 PIP provides for annual and long-term incentive awards to eligible employees of Altria or its subsidiaries or affiliates. Awards may be paid in the form of cash, shares of common stock or any combination thereof, as determined by the Compensation and Talent Development Committee of the Board. Twenty-five million shares of Altria’s common stock are reserved for awards under the 2025 PIP.
    The 2025 Non-Employee Director Plan provides for awards to members of the Board who are not full-time employees of Altria or its subsidiaries. Awards may be paid in cash, stock options, other stock-based awards or any combination thereof, as determined by the Nominating, Corporate Governance and Social Responsibility Committee of the Board. One million shares of Altria’s common stock are reserved for awards under the 2025 Non-Employee Director Plan.
    The material terms of the 2025 PIP and the 2025 Non-Employee Director Plan are described under “Proposal 4 – Approval of the 2025 Performance Incentive Plan” and “Proposal 5 – Approval of the 2025 Stock Compensation Plan for Non-Employee Directors,” respectively, in the 2025 Proxy Statement. These descriptions are incorporated by reference in this Current Report on Form 8-K.
    The descriptions of the material terms of the 2025 PIP and the 2025 Non-Employee Director Plan are qualified in their entirety by reference to the full text of the 2025 PIP and the 2025 Non-Employee Director Plan, which are filed as Exhibits 10.1 and 10.2, respectively, and incorporated by reference in this Current Report on Form 8-K.
    2


    Item 5.07.    Submission of Matters to a Vote of Security Holders.
    There were 1,387,662,634 shares of Altria’s common stock represented in person or by proxy at the Annual Meeting, constituting 82.28% of outstanding shares on March 25, 2025, the record date for the Annual Meeting. The matters voted upon at the Annual Meeting and the final voting results are set forth below:
    Proposal 1:    Election of 11 Directors.
    NameForAgainstAbstainBroker Non-Vote
    Ian L.T. Clarke1,033,982,9237,714,3293,465,593342,499,789
    Marjorie M. Connelly1,029,744,40612,333,7333,084,706342,499,789
    R. Matt Davis1,034,528,9337,311,6073,322,305342,499,789
    William F. Gifford, Jr.1,031,009,48511,010,4283,142,932342,499,789
    Debra J. Kelly-Ennis1,009,718,25232,101,3633,343,230342,499,789
    Kathryn B. McQuade1,012,527,81529,329,3273,305,703342,499,789
    George Muñoz1,003,665,66638,136,4643,360,715342,499,789
    Virginia E. Shanks1,033,387,0428,587,7453,188,058342,499,789
    Richard S. Stoddart1,035,420,1606,272,2823,470,403342,499,789
    Ellen R. Strahlman1,034,113,5837,862,3603,186,902342,499,789
    M. Max Yzaguirre1,030,462,52811,422,9953,277,322342,499,789
    All nominees were duly elected as directors of Altria.
    Proposal 2:    Ratification of the Selection of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025.
    ForAgainstAbstain
    1,332,443,94049,918,3875,300,307
    The selection of the independent registered public accounting Firm was ratified.
    Proposal 3:    Non-Binding Advisory Vote to Approve the Compensation of Altria’s Named Executive Officers.
    ForAgainstAbstainBroker Non-Vote
    986,172,10950,685,5548,305,182342,499,789
    The proposal was approved on an advisory basis.
    Proposal 4:    Approval of the 2025 Performance Incentive Plan.
    ForAgainstAbstainBroker Non-Vote
    990,629,15147,123,7157,409,979342,499,789
    The 2025 PIP was approved.
    Proposal 5:     Approval of the 2025 Stock Compensation Plan for Non-Employee Directors.
    ForAgainstAbstainBroker Non-Vote
    1,010,788,04326,417,7707,957,032342,499,789
    The 2025 Non-Employee Director Plan was approved.
    3


    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits
    10.1
    2025 Performance Incentive Plan (incorporated by reference to Exhibit A to Altria Group, Inc.’s Definitive Proxy Statement on Schedule 14A filed on April 3, 2025 (File No. 1-08940)).
    10.2
    2025 Stock Compensation Plan for Non-Employee Directors (incorporated by reference to Exhibit B to Altria Group, Inc.’s Definitive Proxy Statement on Schedule 14A filed on April 3, 2025 (File No. 1-08940)).
    104
    Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).

    4



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ALTRIA GROUP, INC.
    By:/s/ W. HILDEBRANDT SURGNER, JR.
    Name:W. Hildebrandt Surgner, Jr.
    Title:Vice President, Corporate Secretary and
    Associate General Counsel
                            

    DATE:    May 19, 2025

    5
    Get the next $MO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    11/10/2022$38.00Neutral → Sell
    UBS
    6/29/2022$53.00 → $36.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:08:44 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:03:21 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Financials

    Live finance-specific insights

    See more
    • Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

      Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

      5/15/25 1:30:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

      Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

      4/29/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Declares Regular Quarterly Dividend of $1.02 Per Share

      Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.02 per share, payable on April 30, 2025 to shareholders of record as of March 25, 2025. The ex-dividend date is March 25, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20250227441410/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

      2/27/25 3:00:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

      Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

      5/15/25 1:30:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria to Host Webcast of 2025 Annual Meeting of Shareholders

      Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast of its 2025 Annual Meeting of Shareholders ("2025 Annual Meeting" or "meeting") on Thursday, May 15, 2025 at 9:00 a.m. Eastern Time. The 2025 Annual Meeting will be held virtually via live webcast. During the meeting, shareholders as of the 2025 Annual Meeting record date (March 25, 2025) will be able to vote their shares electronically and will be able to submit questions during the meeting as time permits. Although shareholders will be able to vote their shares during the meeting, they are encouraged to do so before the meeting using one of the methods described in the 2025 Proxy Statement. If you are not a shareholder

      5/1/25 10:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

      Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

      4/29/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Altria downgraded by Deutsche Bank

      Deutsche Bank downgraded Altria from Buy to Hold

      4/1/25 3:04:54 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Morgan Stanley initiated coverage on Altria with a new price target

      Morgan Stanley initiated coverage of Altria with a rating of Equal-Weight and set a new price target of $54.00

      1/16/25 7:47:52 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria upgraded by BofA Securities with a new price target

      BofA Securities upgraded Altria from Neutral to Buy and set a new price target of $65.00 from $55.00 previously

      12/6/24 7:56:47 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    SEC Filings

    See more
    • Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

      5/19/25 8:41:28 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Altria Group Inc.

      10-Q - ALTRIA GROUP, INC. (0000764180) (Filer)

      4/29/25 7:26:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

      4/29/25 7:03:23 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/13/24 4:58:48 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/13/23 2:49:28 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/9/23 10:54:46 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    See more
    • Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

      Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

      2/26/24 4:30:00 PM ET
      $ARIS
      $MO
      $PXD
      Oilfield Services/Equipment
      Energy
      Medicinal Chemicals and Botanical Products
      Health Care
    • Seasoned Financial Expert Max Yzaguirre Named Strategic Advisor of FireFly Automatix, Leader in AV and EV-Driven Professional Turfgrass Mowing Technology

      -Yzaguirre joins a list of seasoned professionals on FireFly's team with specific expertise in initiating and growing businesses in evolving market conditions- FireFly Automatix, Inc., the de facto industry leader in AV and EV professional turfgrass mowing technology, today announced the appointment of financial and leadership expert M. Max Yzaguirre as a strategic advisor to CEO Andrew Limpert and the board of directors. Yzaguirre's appointment follows the recent additions of former WPP Group CFO Paul Richardson and capital markets professional Liz Hocker to FireFly's board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202401

      1/23/24 9:00:00 AM ET
      $ARIS
      $LBC
      $MO
      Oilfield Services/Equipment
      Energy
      Major Banks
      Finance
    • Altria Group, Inc. Announces Retirement of Director Nabil Y. Sakkab From Board of Directors

      Nabil Y. Sakkab, a director of Altria Group, Inc. ("Altria") since 2008, will retire from service on our Board of Directors following the completion of his current term. Consequently, Mr. Sakkab will not stand for re-election to the Board of Directors at Altria's 2024 Annual Meeting of Shareholders, which Altria anticipates holding on May 16, 2024. "Nabil's contributions have significantly benefited Altria over the past 15 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank him for his long and distinguished service and wish him the very best upon his retirement." Dr. Sakkab is Chair of the Innovation Committee and is a member of the Executive, Finance, and

      10/25/23 4:30:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yzaguirre Mario Max was granted 3,219 shares, increasing direct ownership by 25% to 16,252 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      5/19/25 3:06:43 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Strahlman Ellen R was granted 3,219 shares, increasing direct ownership by 16% to 23,087 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      5/19/25 3:05:17 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Stoddart Richard S was granted 3,219 shares (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      5/19/25 3:03:40 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care